PAP
GPCR icon

Persistent Asset Partners’s Structure Therapeutics GPCR Stock Holding History

Persistent Asset Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-512
Closed -$1.96M – 387
2025
Q4 		$1.96M Buy
+512
New +$20.9K 0.88% 20

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Persistent Asset Partners's GPCR Position: Q1 2026 in Review

Persistent Asset Partners increased its Structure Therapeutics (GPCR) stake by 650% in Q1 2026, buying an estimated $1.08M and bringing the position to 18,263 shares worth $880K. The position accounts for 0.33% of the portfolio, ranked #77.

Persistent Asset Partners first reported a position in GPCR in Q4 2025 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Persistent Asset Partners held 18,263 shares of Structure Therapeutics worth $880K as of Q1 2026.
  • Persistent Asset Partners bought 15,827 Structure Therapeutics shares in Q1 2026, an estimated $1.08M.
  • Structure Therapeutics made up 0.33% of Persistent Asset Partners's portfolio in Q1 2026, its #77 holding.
  • Persistent Asset Partners first reported a position in Structure Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.